Genmab reported second-quarter revenue of $1.16 billion, up 25% year over year. Management raised its 2026 revenue guidance by approximately 460 basis points at the midpoint to $4.4 billion and lifted adjusted operating expense guidance by about 250 basis points to $2.9 billion.
Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.
Large acquisitions and heavier R&D spending increase financial risk if new drugs fail to meet expectations or achieve meaningful commercial uptake.
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.33 | 48.40 | 14.15 |
Price/Book Value | 3.41 | 1.20 | 4.02 |
Price/Sales | 5.10 | 1.97 | 4.47 |
Price/Cash Flow | 20.74 | 11.00 | 11.26 |
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.44 | 0.54 | 4.31 |
Current Ratio | 2.46 | 1.14 | 4.59 |
Interest Coverage | 3.88 | 0.07 | 791.55 |
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 11.74% | 5.53% | 26.83% |
Return on Equity (Normalized) | 21.07% | 11.34% | 35.48% |
Return on Invested Capital (Normalized) | 14.75% | 7.74% | 33.21% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?cSBQp | LOCK|Dh>!H | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Gnc!>^ | LOCK|GJ&N | $85B | |||
| argenx SE ADR
ARGX
| LOCK|mhnLNJ | LOCK|&^ | $65B | |||
| Moderna Inc
MRNA
| LOCK|HHNCCs | LOCK|TRN | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Dm>J@%% | LOCK|b% | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$S!@%r | LOCK|x>!^ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xb<qq@z@ | LOCK|%Y#Z | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|T%MHx^K | LOCK|gw | $26B | |||
| Incyte Corp
INCY
| LOCK|p!gV<w? | LOCK|DtH | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?%f^?tD | LOCK|Jzz | $16B |
United States